All Posts

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

Jan 8, 2026

•

8 min read

What does it mean to be a "platform technology"?

Jan 7, 2026

•

5 min read

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Jan 6, 2026

•

9 min read

Day #1: The Biotech 165 Challenge Begins

Jan 5, 2026

•

13 min read

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Dec 19, 2025

•

11 min read

Putting ASX Healthcare in the Hot Seat in 2026

Dec 18, 2025

•

6 min read

Same Result. Two Markets. Very Different Answers.

Dec 17, 2025

•

9 min read

The Holiday Trade I like to do once a Year

Dec 16, 2025

•

7 min read

Trump floats new cannabis rules: Weeding out the good from the bad

Dec 15, 2025

•

11 min read

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Dec 12, 2025

•

9 min read

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Dec 11, 2025

•

9 min read

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Dec 10, 2025

•

9 min read

1...9 10 11 12

All Posts

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

What does it mean to be a "platform technology"?

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Day #1: The Biotech 165 Challenge Begins

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Putting ASX Healthcare in the Hot Seat in 2026

Same Result. Two Markets. Very Different Answers.

The Holiday Trade I like to do once a Year

Trump floats new cannabis rules: Weeding out the good from the bad

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

The Armchair Analyst